Jones Collombin Investment Counsel Inc decreased its stake in Pfizer Inc. (NYSE:PFE) by 6.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 345,515 shares of the biopharmaceutical company’s stock after selling 22,200 shares during the period. Pfizer makes up 3.6% of Jones Collombin Investment Counsel Inc’s investment portfolio, making the stock its 14th largest position. Jones Collombin Investment Counsel Inc’s holdings in Pfizer were worth $12,166,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of the company. Jag Capital Management LLC bought a new position in shares of Pfizer during the second quarter valued at approximately $202,000. Lynch & Associates IN raised its position in shares of Pfizer by 8.2% in the second quarter. Lynch & Associates IN now owns 165,041 shares of the biopharmaceutical company’s stock valued at $5,811,000 after buying an additional 12,443 shares during the period. McQueen Ball & Associates Inc. raised its position in shares of Pfizer by 0.6% in the second quarter. McQueen Ball & Associates Inc. now owns 58,397 shares of the biopharmaceutical company’s stock valued at $2,056,000 after buying an additional 360 shares during the period. QUANTRES ASSET MANAGEMENT Ltd bought a new position in shares of Pfizer during the second quarter valued at approximately $243,000. Finally, TNB Financial raised its position in shares of Pfizer by 59.1% in the second quarter. TNB Financial now owns 49,193 shares of the biopharmaceutical company’s stock valued at $1,732,000 after buying an additional 18,265 shares during the period. 69.66% of the stock is owned by hedge funds and other institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.31% during mid-day trading on Friday, hitting $32.66. 15,569,339 shares of the company were exchanged. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39. The stock’s 50 day moving average is $34.02 and its 200-day moving average is $34.27. The company has a market cap of $198.10 billion, a price-to-earnings ratio of 28.95 and a beta of 0.86.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. Pfizer’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the company posted $0.56 earnings per share. Equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. Pfizer’s payout ratio is 95.24%.
Several equities analysts recently commented on the stock. Vetr lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 price target for the company. in a research report on Thursday. Jefferies Group lowered shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price target for the stock from $39.00 to $36.00 in a research report on Thursday. Argus reaffirmed a “buy” rating and set a $39.00 price target on shares of Pfizer in a research report on Tuesday, October 4th. Bank of America Corp. reaffirmed a “buy” rating and set a $40.00 price target on shares of Pfizer in a research report on Tuesday, September 27th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Pfizer currently has an average rating of “Buy” and an average price target of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.